Skip to main content
An official website of the United States government

nezastomig

A bispecific antibody directed against both the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA) and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration of nezastomig this bispecific antibody binds to both CD28 on cytotoxic T lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which may result in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.
Synonym:anti-PSMA/anti-CD28 bispecific antibody REGN5678
anti-PSMA/CD28 bispecific antibody REGN5678
anti-PSMAxCD28 antibody REGN5678
Code name:REGN 5678
REGN-5678
REGN5678
Search NCI's Drug Dictionary